Cantor Fitzgerald Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)
Stock analysts at Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 115.27% from the company’s previous […]
Stock analysts at Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 115.27% from the company’s previous […]
